BIP_CFTY720D2403

BIP CFTY720D2403-Long-term, Prospective, Multinational, Parallel-cohort Study Monitoring Safety in Patients With MS Newly Started With Fingolimod Once Daily or Treated With Another Approved Disease-modifying Therapy

The purpose of this world-wide prospective parallel-cohort study in patients with relapsing forms of Multiple Sclerosis, either newly treated with fingolimod or receiving another disease-modifying therapy, is to further explore the incidence of selected safety-related outcomes and to further monitor the overall safety profile of fingolimod under conditions of routine medical practice.

Key Eligibilities:
-Patients with relapsing forms of MS that have been recently initiated on fingolimod by their treating physician.
-Starting fingolimod at time of study entry.

Exclusion Criteria:
-Previously or currently treated with natalizumab or a cytotoxic agent (e.g. mitoxantrone, cladribine, alemtuzumab).

**Other protocol-defined inclusion/exclusion criteria may apply. Please click on the NCT Number (below) to learn more about the study at clinicaltrials.gov.**
Phase IV
NCT01442194
Neurosciences, All Other
Multiple Sclerosis
Stanley Cohan, M.D., Ph.D.
Novartis
Lynette Currie
  • Providence St. Vincent Medical Center